Latest It Compliance News

VanEck Investments Limited has issued a comprehensive Replacement Product Disclosure Statement for eight of its Australian ETFs, detailing investment strategies, fees, risks, and operational protocols under ASX AQUA Rules.

Strata Minerals has secured a binding agreement with BML Ventures to fund and manage mining at its Zelica Gold Project, paving a capital-light path to production and profit sharing.

Coda Minerals has secured $6.7 million through an oversubscribed placement to fast-track its Pre-Feasibility Study at Elizabeth Creek, underpinning key technical and environmental programs.

A US court has dismissed Identitii's patent infringement claim against JPMorgan Chase, citing patent ineligibility. Identitii plans to appeal, while its core business remains unaffected.

Vection Technologies secures a $3.3 million order from Media Comunicazione for its Accessibility Kiosk platform, adding a third profitable revenue stream to its FY26 momentum alongside defence and AI businesses.

IDP Education (ASX:IEL) has responded to an ASX price query following a sharp share price fall and increased trading volume, attributing the movement to a late analyst downgrade and confirming compliance with continuous disclosure rules.

ANZ Bank New Zealand has lodged an appeal against a High Court summary judgment in a class action related to consumer credit laws, prolonging legal uncertainty for the lender.

Bass Oil Limited offers up to 24 million free attaching options to recent placement participants, alongside nearly 8 million options to its lead manager PAC Partners, with no new funds raised from the options issue.

New Talisman Gold Mines boosted revenue by 121% to NZ$53,000 but posted a $2.26 million net loss as it commissioned a processing plant and secured key commercial agreements.

Elanor Investors Group has called off its planned acquisition of Singapore-based Firmus Capital due to prolonged regulatory delays, while reaffirming its $125 million recapitalisation with Rockworth Capital Partners and seeking ASX trading reinstatement.

PolyNovo has completed its pivotal US clinical trial report for NovoSorb BTM and adjusted its FDA Premarket Approval submission timeline to late 2026 to incorporate updated regulatory requirements and additional data.

Arafura Rare Earths has successfully completed the first tranche of its A$350 million placement, issuing 675.1 million shares and raising approximately A$175.5 million before costs. The second tranche awaits shareholder approval.